For the identification of predictive biomarkers that are useful to detect these patients with worse prognoses, we performed a comprehensive kinase activity analysis using PamStation 12 (PamGene International, BJ’s-Hertogenbosch, The Netherlands) in NSCLC patients at advanced stages with sensitizing EGFR mutations and followed their prognosis prospectively. This evidence concerns the gene EGFR and non-small cell lung carcinoma.